BEMA Buprenorphine/Naloxone: Pivotal trial completed enrollment

BioDelivery Sciences completed enrollment in the 2-way crossover, pivotal BNX-103 trial comparing BEMA Buprenorphine/Naloxone to sublingual Suboxone Buprenorphine/Naloxone in healthy volunteers. In February, BioDelivery said it reached an agreement with FDA on the development program for BEMA Buprenorphine/Naloxone, which includes BNX-103, the Phase I BNX-106 trial and an open-label safety study (see BioCentury, March 5). BioDelivery reported data from BNX-106 in June, while the safety study is expected to complete enrollment of about 400 patients next quarter (see BioCentury, July 16). ...